AT13410U1 - Use of a ubiquinone component and a combined preparation to improve female fertility - Google Patents

Abstract

The invention relates to the use of at least one ubiquinone-10 component for the preparation of a combination preparation, in particular of several active ingredients, for improving the egg quality and egg maturity and a combination preparation with said effect comprising at least the active ingredients C vitamins, E vitamins, B1 vitamins , B2 vitamins, B5 vitamins, B6 vitamins, B9 vitamins, B12 vitamins, D vitamins, at least one Ubiquinone 10 component is included.

Description

Austrian Patent Office AT13 410U1 2013-12-15

Description: The invention relates to the use of at least one ubiquinone-10 component for the preparation of a combination preparation, in particular of several active substances, for improving egg cell quality and a combination preparation for improving oocyte quality comprising at least the active ingredients C vitamins, E vitamins, B1 Vitamins, B2 Vitamins, GI Vitamins, B6 Vitamins, B9 Vitamins, B12 Vitamins and D Vitamins.

More and more couples the way to the desired child is difficult. In industrialized countries such as Germany and the USA, one in ten couples is unintentionally childless and the trend is rising. Limited fertility can have many causes. The increasing age of couples wishing to have children may play a role as well as environmental pollution, reduced sperm quality, impaired ova, unhealthy lifestyles and others. Also called "lifestyle factors" For women and men, one of the prerequisites for fertility is adequate supply of the body with certain micronutrients, energy substrates and vitamins. An adequate supply of vitamins and certain nutrients is unfortunately increasingly difficult in our time. With increased stress in everyday life with stress, low food quality and unhealthy diet, the human organism is often inadequately supplied. As a result, the body is under constant stress and this is particularly true where the cells are most sensitive - in the egg and sperm cells. The male sperm become sluggish, oocytes "miss". their ovulation and thus fertility may suffer from malnutrition. It has already been proven in several studies, how much the right nutrition contributes to the fulfillment of the desire to have children.

While the woman is already born with the egg cells, the sperm are mimicked in the man for a lifetime. Therefore, it is important for the woman to prepare her body for pregnancy. There are a variety of combination preparations.

In them is a combination of micronutrients, which are necessary for the healthy development of oocytes.

For example, from US 2007/0104801 A1 a means for maintaining and increasing female fertility is known, which in addition to glucosamine also selenium, folic acid, vitamin B6, vitamin B12, iron, zinc, magnesium, green tea, chaste tree and Contains hyaluronic acid. US Pat. No. 6,569,857 B1 also discloses a dietary supplement for increasing the conception probability and for supporting a normal development of an embryo, whereby besides the vitamins E, C, B1, B2, B3, B6, B9, B12, also β-carotene, iron, copper , Zinc, calcium, magnesium, linolenic acid and DHA can be included.

Before and during pregnancy, a sufficient supply of essential nutrients and vitamins to the respective stage is conducive to the health of the growing baby. However, in some cases, excessive, random vitamin intake may even be detrimental to egg cell quality.

The object of the present invention is therefore to provide an active ingredient or a combination preparation which improves the egg cell quality.

The object of the invention is in each case independent by the use of at least one ubiquinone-10 component for the preparation of a combination preparation, in particular of several active substances, and a combination preparation comprising at least the active ingredients C-vitamins (ascorbic acid), E-vitamins, B1- Vitamins (thiamine), B2 vitamins (riboflavin), B5 vitamins (pantothenic acid), B6 vitamins (pyridoxine), B9 vitamins (folic acid), B12 vitamins (cobalamin) and D vitamins, with at least one ubiquinone-10 Component is included, solved. The advantage here is that the supplementation of a ubiquinone-10 component benefits the female ovaries, thus improving both egg cell quality and egg cell maturity. The Ubiqutnon-10 component is an important micronutrient for the mitochondria. 1/12 Austrian Patent Office AT13 410U1 2013-12-15 has the most germ cells of all body cells with most mitochondria. Damage to the mitochondria leads on the one hand to lower energy supply and on the other hand to increase oxidative stress and thus to the formation of oxygen radicals in the oocytes. The additional intake of a ubiquinone-10 component has been shown to benefit the ovaries. In addition, it is advantageous for the combination preparation that the specific combination of the selected active ingredients shows better results in comparison to the individual substances. Oxygen radicals, which are formed as already mentioned, attack the egg cell membrane. Furthermore, they impede mitochondrial function and adversely affect the integrity of DNA and RNA as well as the formation and function of cellular proteins. Many vitamins, especially vitamins C and E have been shown to have high antioxidant potential. Among other things, vitamins B6, B12 and folic acid of the B complex have a regulating effect on homocysteine metabolism. This has a positive effect on the vascular function and thus supports a sufficient circulation of the ovaries. Also, the implantation of the embryo in early pregnancy is positively influenced by a balanced homocysteine metabolism. In particular, in patients with a folate metabolic disorder (MTHFR gene mutation), the formation of microthrombi can be reduced during implantation and thus the early laboratory rate can be reduced by the vitamin B series. Vitamins of the D complex show beneficial effects on the hormonal system and on the calcium metabolism, which plays an important role during pregnancy (for example, to build up the child's skeletal system).

The combination preparation is preferably used for the treatment of female infertility, especially for women over 35 years, whereby a later desire for children can be supported. Ubiquinone-10 components are needed by the body for, among other things, the generation of energy in the mitochondria. In particular, women of advanced childbearing age show increased mitochondrial damage (Seifer et al, 2002), which on the one hand leads to reduced energy supply and, on the other hand, to increased oxidative stress in the oocytes. This manifests itself in a reduced egg cell quality and impaired early embryonic development. Studies have shown that this is one of the main reasons for the age-related decline in female fertility (Bentov et al, 2010).

To promote the mitochondrial function, a ubiquinone component is used in the combination preparation. Ubiquinone 10 components are very good antioxidants, but are also needed by the body for energy in the mitochondria. Pignatti et al showed in 1980 that the tissue concentration of ubiquinone decreases with age. Santos-Ocana confirmed earlier observations in 2002 that make it clear that Ubiquinone is very important for mitochondrial energy delivery.

The ubiquinone-10 component may consist of ubiquinone-10 or ubiquinol or a mixture of these compounds, it being possible for ubiquinol to be absorbed more rapidly and thus be available immediately.

Advantageously, the ubiquinone-10 component proves to be administered in daily doses of 20 mg to 100 mg, in particular 30 mg to 50 mg, preferably 35 mg to 40 mg, thus ensuring that an appropriate level of ubiquinone-10 Component is present in the organism and thus can support mitochondrial function, especially in the ovaries done. This promotes good egg cell quality.

The ubiquinone-10 component is contained in amounts of 2 to 25 wt .-%, in particular 5 to 15 wt .-%, preferably 8 to 12 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation , which on the one hand gives a sufficient effect of the Ubiquinon 10 component but on the other hand, there is no risk of overdose. Due to the selected proportion by weight, there is also good processability in the preparation of the combination preparation.

The combination preparation can be used both as a drug or balanced diet and as a dietary supplement, which is guaranteed for the user in the approval as a drug or balanced diet that the preparation at least one Austrian Patent Office AT 13 410 Ul It has been undergoing a clinical trial and, when approved as a dietary supplement, provides easy and possibly discrete access to the product.

By the inventive selection of the amounts of active ingredients such as C-vitamins in amounts of 4 to 60 wt .-%, in particular 10 to 45 wt .-%, preferably 19 to 31 wt .-%, E-vitamins in amounts from 1 to 15 wt .-%, in particular 2 to 10 wt .-%, preferably 3 to 6 wt .-%, B1 vitamins in amounts of 0.1 to 3 wt .-%, in particular 0.2 to 2 wt .-%, preferably 0.3 to 0.9 wt .-%, B2 vitamins in amounts of 0.1 to 3 wt .-%, in particular 0.2 to 2 wt .-%, preferably 0.3 to 0 , 9 wt .-%, B5 vitamins in amounts of 0.5 to 10 wt .-%, in particular 1 to 5 wt .-%, preferably 2 to 3 wt .-%, B6 vitamins in amounts of 0.1 to 5% by weight, in particular 0.5 to 3% by weight, preferably 0.8 to 1.3% by weight, of B9 vitamins in amounts of from 0.01 to 1% by weight, in particular 0, From 05 to 0.5% by weight, preferably from 0.1 to 0.3% by weight, of B12 vitamins in amounts of from 0.0003 to 0.01% by weight, in particular from 0.0009 to 0.005% by weight %, preferably 0.001 to 0.008 wt .-%, D vitamins in amounts of from 0.0002 to 0.01 wt .-%, esp another 0.0008 to 0.008 wt .-%, preferably 0.001 to 0.005 wt .-%, and a Ubiquinon-10 component in amounts of 2 to 25 wt .-%, in particular 5 to 15 wt .-%, preferably 8 to 12 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation, show beneficial effects on egg maturity, egg cell quality, fertility, and support early embryonic development. The effectiveness of the combination preparation is based not only on the antioxidant activity of selected individual substances, but also on numerous other factors, such as. the correct delivery, in particular the delayed release of C-vitamins. The development and maturation of the egg cell is dependent on the presence of a certain amount of oxygen radicals, which is why vitamin C is included. In addition, good protection against oxidative stress is provided by a time-delayed release which does not start completely immediately after taking the combination preparation. Due to the balance and the correct composition, the desired effect can be achieved.

Also advantageous is the addition of niacin in amounts of 1 to 20 wt .-%, in particular 3 to 15 wt .-%, preferably 5 to 11 wt .-%, zinc and / or a zinc compound in amounts of 0 From 2 to 5% by weight, in particular from 1 to 4.5% by weight, preferably from 1.5 to 3.5% by weight, of magnesium and / or of a magnesium compound in amounts of from 10 to 50% by weight, in particular 15 to 40 wt .-%, preferably 25 to 35 wt .-%, calcium and / or a calcium compound, in amounts of 5 to 50 wt .-%, in particular 15 to 40 wt .-%, preferably 20 to 33 wt % and / or nicotinamide in amounts of 1 to 15% by weight, in particular 2 to 10% by weight, preferably 3 to 6% by weight, iodine and / or an iodine compound in amounts of 0.001 to 0, 1 wt .-%, in particular 0.007 to 0.08 wt .-%, preferably 0.01 to 0.05 wt .-%, iron and / or an iron compound in amounts of 0.5 to 10 wt .-%, in particular 1 to 5 wt .-%, preferably 1.5 to 3 wt .-%, B7 vitamins (biotin) in amounts of 0.001 to 0.5 wt .-%, esp particularly 0.007 to 0.1 wt .-%, preferably 0.01 to 0.08, based on the total weight of the therapeutically active agents of the combination preparation, because characterized the previously described beneficial effects are expressed cumulatively on the development of the egg. The described composition of the combination preparation optimizes the interaction of the individual substances with one another and additionally reinforces the synergy effects. In addition, a balanced interaction with the other substances can be achieved. Niacin and nicotinamide, for example, enhance the antioxidant effect and support the regeneration of the DNA. For other substances, which are increasingly needed during pregnancy, such as magnesium, is given before the onset of adequate care. Iron improves women's fertility, and iodine has an effect on hormone balance.

The addition of further trace elements selected from a group comprising selenium and / or a selenium compound in amounts of 0.001 to 0.05 wt .-%, in particular 0.002 to 0.01 wt .-%, preferably 0.003 to 0.005 wt. -%, copper and / or a copper compound in amounts of 0.05 to 3 wt .-%, in particular 0.08 to 1 wt .-%, preferably 3/12 Austrian Patent Office AT13 410U1 2013-12-15 0.1 bis 0.5 wt .-%, molybdenum and / or a molybdenum compound in amounts of from 0.0001 to 0.5 wt .-%, in particular 0.001 to 0.1 wt .-%, preferably 0.002 to 0.05 wt .-% , Chromium and / or a chromium compound in amounts of 0.0001 to 0.5 wt .-%, in particular 0.001 to 0.1 wt .-%, preferably 0.002 to 0.05 wt .-%, phosphorus and / or a phosphorus compound in amounts of 0.1 to 30% by weight, in particular 1 to 20% by weight, preferably 10 to 15% by weight, manganese and / or a manganese compound in amounts of 0.05 to 3% by weight, in particular 0.08 to 1 wt .-%, preferably 0.1 to 0.5 wt .-%, bezo gene on the total weight of the therapeutically active agents of the combination preparation, the beneficial effects on the egg, especially the egg quality can be further improved. Trace elements are essential nutrients for humans, the absence of which can cause severe deficiency symptoms.

Also advantageous is the addition of precursors of A vitamins, in particular a- and ß-carotene, a- and ß-Cryptoxanthin and lycopene, in amounts of 0.0001 to 0.05 wt .-%, in particular 0 , 0002 to 0.001 wt .-%, preferably 0.0003 to 0.0008 wt .-%, and / or K vitamins, in particular K1, K2, K3 in amounts of 0.05 to 3 wt .-%, in particular 0 , 08 to 1 wt .-%, preferably 0.1 to 0.5 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation, because the use of estrogen, the utilization of A vitamins may be disturbed and by admixture of A. Nonetheless, vitamins for the combined preparation are sufficient to supply A vitamins and can therefore exert their positive effects on growth.

Are omega-3 fatty acids, in particular DHA and / or EPA, in amounts of 2 to 70 wt .-%, in particular 10 to 50 wt .-%, preferably 20 to 40 wt .-%, based on the total weight contain the therapeutically active agents of the combination preparation, it is ensured before the onset of pregnancy that adequate care is given and thus the increased need during pregnancy is already covered at the beginning. However, administration of omega-3 fatty acids is not recommended until the third month of pregnancy and can then also promote the neurological development of the fetus.

By the addition of probiotics in amounts of 0.1 to 10 wt .-%, in particular 0.5 to 5 wt .-%, preferably 1 to 3 wt .-%, based on the total weight of the therapeutically active agents of Combination preparation is achieved in that the mucosal immune system is stimulated or modulated. Even vaginal infections can be positively influenced by probiotics and thus create a more favorable environment for pregnancy.

For the purposes of the invention are understood by pre-A, B, C, D and E vitamins all known representatives of these vitamins. For example, E-vitamins are said to comprise toco-pherols, tocotrienols and tocomonoenols. By the term D-vitamins in particular vitamin D3, 25 (OH) vitamin D3 and calcitriol are included. This is mentioned only as an example and also applies to the other vitamins mentioned in the invention.

The same as described above also applies to the other active substances mentioned in the invention, where their derivatives or salts should also be included, which are bioavailable to the body for disposition.

The present invention describes, inter alia, the positive effect of ubiquinone-10 components on the oocyte, in particular the maturation of the oocyte and the early embryonic development and implantation. A Ubiquinone-10 component is required by the body for, among other things, energy production in the mitochondria. It is an important micronutrient for the support of mitochondrial health. Of all body cells, the female ova have the most mitochondria. However, women of advanced childbearing age, in particular, show increased mitochondrial damage leading, on the one hand, to reduced energy supply and, on the other hand, to increased oxidative stress in the oocytes. This manifests itself in a reduced egg cell quality. This is a major cause of the age-related decline in female fertility. The ubiquinone-10 components decrease with age and this explains the beneficial effect of ubiquinone supplementation in women over 35 with desire to have children. Ubiquinone 4/12 Austrian Patent Office AT 13 410 Ul 2013-12-15 10 components are also an important antioxidant.

Various processes such as environmental pollution, malnutrition, radiation and other stresses lead to oxidative stress in the body. This refers to the damage to the cells by oxygen radicals and other reactive oxygen species, especially the germ cells, sperm and egg cells, are particularly susceptible here. Like male fertility, female fertility is also adversely affected by oxidative stress. The normal age-related decline in women's fertility is related, inter alia, to oxidative damage. This could be proved beyond doubt by scientific studies. Usually, the body has a number of its own defense mechanisms, including the body's own antioxidants - but these are, especially in advanced age, not always sufficiently available.

The combination preparation according to the invention is specially developed for the needs of the female body in children and pregnancy. It can be both a dietary supplement, a dietary supplement for special medical purposes (complementary balanced diet), as well as a medicinal product.

Owing to the combination preparation according to the invention, oocytes are protected from harmful influences by oxidative stress and at the same time supplied with the nutrients and minerals necessary for the development in order to enable them to develop as best as possible.

Furthermore, the combination preparation according to the invention shows a specially adapted mixture of antioxidants, partly in depot form, and other important for the reproductive cells nutrients and minerals. For example, vitamin C is added as a sustained-release form. Preparations for a sustained release of active ingredients are described in the prior art. For example, vitamin C may be coated with hydroxypropylmethylcellulose. Thus, a phase-appropriate care of the woman in particular before but also during pregnancy is available. Of course, other known from the prior art methods for the delayed release of vitamin C can be applied.

The mechanisms of action of the individual substances in the combination preparation according to the invention are complex. In addition to nutrient administration and enzyme induction, an essential mechanism of action is the targeted reduction of oxygen radicals.

All the individual substances in the combination preparation according to the invention have been shown in studies that an additional intake of the coordinated in the combination preparation according to the invention antioxidants in women leads to a significant improvement in their fertility.

The mechanisms described above work preferably in combination of the active ingredients and by supporting several antioxidants. Other substances such as zinc, which is involved in almost all biochemical processes in the body, support the effect of the combination preparation according to the invention.

Due to the synergistic effect of the individual active ingredients in the selected quantitative ranges, the effectiveness with respect to egg cell quality and egg maturity of the combination preparation according to the invention can be achieved.

The use of Ubiquinon-10 components as well as the combination preparation according to the invention is preferably recommended for oral administration. The preparation can be used both as a human and veterinary product.

In the table below, the amount ranges of the recommended daily dose of the individual relevant for the invention agents are given. Preferably, the combination preparation according to the invention is taken as one capsule per day. However, the drug levels can be chosen so that two capsules per day are required to reach the recommended dosage. 5/12 Austrian Patent Office AT13 410U1 2013-12-15

Active substance Recommended amount range in mg per day Vitamin C 80 -1 20 Vitamin E 10-30 Vitamin B1 1 -3 Vitamin B2 1,5-3 Vitamin B5 6-18 Vitamin B6 3-5 Vitamin B12 0,005 - 0,008 Vitamin B9 0,6 - 0.8 Vitamin D 0.003 - 0.006 Niacin 15-40 Vitamin B7 0.1 -0.2 Zinc 5-20 Magnesium 100-300 Iodine 0-0.15 Iron 5-15 Ubiquinone-10 Component 30-50 Selenium 0, 01 - 0.05 Calcium 100-400 Omega-3 fatty acids 200 - 500 Vitamin A 0.01 -0.5 Nicotinic acid amide 15-36 Vitamin K 0.01 -0.1 Copper 0.5-3 Molybdenum 0.01 -0.1 chromium 0.01-0.1 beta-carotene 1-5 probiotics 0.1-10 phosphorus 50-150 manqane 0.5-3 In the following are exemplary embodiments of the composition of the therapeutically active substances of the combination preparation according to the invention cited that achieves the beneficial effects.

There are also excipients, such as auxiliaries, fillers, carriers, binders, etc., which are required for the technical processability of the combination preparation according to the invention, included. However, these excipients have no therapeutic efficacy and no positive effects on the egg cell quality and are therefore not therapeutically active agents in the context of the invention.

The following tables show 20 embodiments, indicating the ratio of the active ingredients in wt .-%. 6/12 AT 13 410 Ul 2013-12-15 Austrian

Patent Office

Active ingredient 1 2 3 4 5 6 7 8 9 10 Vitamin C - 80 100 120 95 80 100 120 80 100 Vitamin E - 10 20 30 25 10 20 30 10 20 Vitamin B1 - 1 3 3 2.5 1 3 3 1 3 Vitamin B2 - 1.5 3 3 2 1.5 3 3 1.5 3 Vitamin B5 - 6 12 18 15 6 12 18 6 12 Vitamin B6 - 3 4 5 3 3 4 5 3 4 Vitamin B12 - 0.005 0.007 0.008 0.006 0.005 0.007 0.008 0.005 0.007 Vitamin B9 - 0.6 0.8 0.8 0.7 0.6 0.8 0.8 0.6 0.8 Vitamin D - 0.003 0.005 0.006 0.004 0.003 0.005 0.006 0.003 0.005 Niacin - - - - - 15 35 40 15 35 Vitamin B7 - - - - - 0.1 0.2 0.2 0.1 0.2 Zinc - - - - 14 5 5 20 5 5 Magnesium - - - - - 100 100 300 100 100 Iodine - - - - 0,05 0 0,15 0,15 0 0,15 Iron - - - - - 5 7,5 15 5 7,5 Ubiquinone-10 Component 50 30 35 50 40 30 35 50 30 35 Selenium - - - - - - - - - - Calcium - - - - 250 - - - 100 125 Omega-3 fatty acids " &Quot; &Quot; &Quot; &Quot; &Quot; &Quot; &Quot; - " Vitamin A - - - - - - - - - - Nicotinic acid amide " &Quot; &Quot; &Quot; &Quot; &Quot; &Quot; &Quot; 10 20 Vitamin K - - - - - - - - - - Copper - - - - - - - - - Molybdenum - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -Carotene - - - - - - - - - - Probiotics - - - - 4 - - - - - Phosphorus - - - - - - - - - - Manganese - - - - - - - - - Fillers and excipients / / / / / / / / / /

Active ingredient 11 12 13 14 15 16 17 18 19 20 Vitamin C 120 96 80 100 120 85 105 100 115 95 Vitamin E 30 23 10 20 30 11 30 20 21 15 Vitamin B1 3 2 1 3 3 1 3 2 2 1,5 Vitamin B2 3 2 1.5 3 3 1.8 2.9 1.7 2.4 2.9 Vitamin B5 18 10 6 12 18 15 10 6 9 18 Vitamin B6 5 5 3 4 5 5 3.5 3 4.4 4 Vitamin B12 0.008 0.008 0.005 0.007 0.008 0.007 0.008 0.006 0.005 0.005 Vitamin B9 0.8 0.6 0.6 0.8 0.8 0.7 0.8 0.7 0.6 0.6 Vitamin D 0.006 0.004 0.003 0.005 0.006 0.005 0.003 0.006 0.004 0.003 Niacin 40 - 15 35 40 22 - 38 34 17 Vitamin B7 0.2 - 0.1 0.2 0.2 0.15 0.11 0.12 - - Zinc 20 - 5 5 20 - - - - - Magnesium 300 - 100 100 300 100 120 150 230 - Iodine 0,15 - 0 0,15 0,15 - - - - - 7/12 AT13 410U1 2013-12-15 Austrian

Patent Office

Iron 15 - 5 7.5 15 - - - - - Ubiquinone-10 Component 50 42 30 35 50 50 40 32 46 " Selenium - - 0.01 0.03 0.1 - 0.08 - - - Calcium 500 120 100 120 500 - - - - - Omega-3 fatty acids " &Quot; 20 400 1000 - "" 300 " Vitamin A - 0,001 0,001 0,001 0,01 - - - - - Nicotinic acid amide 50 30 10 20 50 - "" &Quot; - Vitamin K - - 0,5 1 10 - 4 - - - Copper - - 0,5 1 10 - - 0,5 - - Molybdenum - - 0,01 0,08 0,5 - - - 0,1 - Chromium - 0,1 0,01 0,06 0,5 0,09 - - - - ß-Carotene - - 0,5 2 10 - - 5 - - Probiotics - - 0 1 5 - - - - - Phosphorus - - 1 125 200 12 - - - - Manganese - - 0.1 1 10 - - 0.9 - - Fillers and excipients / / / / / / / / / / In experiments it was possible to prove that Embodiments 7 and 10 show particularly good effectiveness. So it comes with a composition according to Embodiment 7 by promoting the egg maturation to an increased by about 10% oocyte amount (after stimulation in the context of a reproductive medical treatment) and to about 18% increased fertilization rate. In general, it has been demonstrated that with the preparation according to the invention the oocyte quality is significantly improved in over 70% of women over 35 years.

In the table below, the composition of the active ingredients in absolute terms of a combination preparation according to the invention, which develops the advantageous effects, is described by way of example.

Active ingredient Amount in mg% by weight Amount in mg% by weight Vitamin C 100 21.24666958 100 30.70668362 Vitamin E 20 4.249333917 20 6.141336723 Vitamin B1 (thiamine) 3 0.637400088 3 0.921200509 Vitamin B2 (Riboflavin) 3 0,637400088 3 0,921200509 pantothenic acid B5 12 2,549,60035 12 3,684802034 vitamin B6 (pyridoxine) 4 0,849,867,883 4 1,228267345 vitamin B12 (cobalamin) 0,007 0,001487267 0,007 0,002149468 folic acid 0, 8 0.169973357 0.8 0.245653469 Vitamin D 0.005 0.001062333 0.005 0.001535334 Niacin (nicotinic acid) 35 7.436334355 35 10.74733927 Biotin 0.2 0.042493339 0.2 0.061413367 Zinc 5 1.062333479 5 1.535334181 Magnesium 100 21.24666958 100 30.70668362 Iodine 0.15 0.031870004 0.15 0.046060025 Iron 7.5 1.593500219 7.5 2.303001271 Ubiquinone 10 Component (Coenzyme Q10) 35 7 , 436334355 35 10,74733927 Calcium 125 26,55833698 - - nicotinic acid amide 20 4,249333917 - - 8/12 Austrian Patent Office AT13 410U1 2013-12-15 In a preferred embodiment, the erfindungsge suitable combination preparation of magnesium oxide, L-ascorbic acid, coenzyme Q10 (7.5%), silica gel, iron citrate (5.2%), D-alpha tocopheryl acetate, nicotinamide, calcium D-pantothenate, nicotinic acid, zinc oxide, pyridoxine HCI, thiamine HCI, maltodextrin, riboflavin, thickener gum arabic, sodium citrate, sucrose, corn starch, citric acid, pteroylmogoglutamic acid (0.17%), potassium iodide (0.05%), biotin, antioxidant alpha-tocopherol, stabilizer tricalcium phosphate , Coloring matter titanium dioxide, dye sunset yellow S, cholecalciferol, cyanocobalamin. The capsule shell is preferably formed or coated from cellulose.

The positive effect of ubiquinone-10 components and the combined preparation according to the invention can be used both in preparation for a natural pregnancy and in preparation for insemination, in vitro fertilization and intracytoplasmic sperm injection.

In one alternative, a combination preparation can be prepared which contains no ubiquinone-10 component. In any case, this combination preparation comprises C vitamins, E vitamins, B1 vitamins, B2 vitamins, B5 vitamins, B6 vitamins, B12 vitamins, B9 vitamins, D vitamins and niacin and possibly B7 vitamins, zinc, magnesium , Iodine, iron and / or calcium. The quantitative ranges of the active ingredients are the same as described above.

Below are embodiments of this alternative.

Active ingredient 21 22 23 Vitamin C 100 100 100 Vitamin E 20 20 20 Vitamin B1 3 3 3 Vitamin B2 3 3 3 Vitamin B5 12 12 12 Vitamin B6 4 4 4 Vitamin B12 0.007 0.007 0.007 Vitamin B9 0.8 0.8 0.8 Vitamin D3 0.005 0.005 0.005 Niacin 15 - 15 Vitamin B7 0.2 - 0.2 Zinc 5 - 5 Magnesium 100 - 100 Iodine 0.15 - 0.15 Iron 7.5 - 15 Nicotinamide 20 - 20 Calcium 125 - - [0043] In In a further development of this alternative, the active ingredients such as selenium, omega-3 fatty acids, A vitamins, K vitamins, copper, molybdenum, chromium, b-carotene, phosphorus, manganese and / or probiotics can also be present in the previously described quantitative ranges ,

Also, this alternative shows a good effect on the egg cell quality and the egg maturity, although the success using a Ubiquinon Q10 component, especially in women over 35 is greater.

The combination preparation according to the invention should be taken orally once a day in the form of a capsule. The recommended minimum income is 1 to 3 months. The preparation should then continue to be taken until the 12th week of pregnancy when pregnancy occurs.

All information on ranges of values in the present description should be understood to include any and all sub-ranges thereof, e.g. the indications 1 to 10 are to be understood as meaning that all partial areas, starting from the lower limit and including the upper limit 10, are included. all subregions begin with a lower limit of 1 or greater and end at an upper limit of 10 or less, e.g. 1 to 1.7, or 3.2 to 8.1 or 5.5 to 10.

The embodiments show possible embodiments of the combination preparation, it being noted at this point that the invention is not limited to the specifically illustrated embodiments thereof, but also various combinations of the individual embodiments are mutually possible and this variation possibility due to the teaching of the technical Acting by objective invention in the skill of those working in this technical field is the expert. So are all possible design variants, which are possible by combinations of individual details of the embodiment described, includes the scope of protection.

The task underlying the independent inventive solutions can be taken from the description. 10/12

Claims (11)

Austrian Patent Office AT13 410U1 2013-12-15 Claims 1. A combined preparation comprising at least the active ingredients 100 mg C vitamin, 15 mg - 20 mg E vitamins, 3 mg B1 vitamin, 3 mg B2 vitamin, 12 mg B5 vitamin, 4 mg B6 vitamins, 800 pg B9 vitamin, 7 pg B12 vitamins, 5 pg D vitamins, 35 mg ubiquinone 10 components, 180 pg - 200 pg B7 vitamin, 35 mg niacin, 5 mg zinc and / or a zinc compound, 100 mg of magnesium and / or a magnesium compound, 150 pg of iodine and / or an iodine compound, 7.5 mg of iron and / or an iron compound for use in the treatment of female infertility and to improve oocyte quality, and egg maturation. 2. Combination preparation according to claim 1, characterized in that calcium and / or a calcium compound and / or nicotinamide is included. 3. Combination preparation according to claim 2, characterized in that calcium and / or a calcium compound in amounts of 5 to 50 wt .-%, in particular 15 to 40 wt .-%, preferably 20 to 33 wt .-%, and / or nicotinamide in amounts of 1 to 15 wt .-%, in particular 2 to 10 wt .-%, preferably 3 to 6 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation are included. 4. Combination preparation according to one of claims 1 to 3, characterized in that further trace elements selected from a group comprising selenium and / or a selenium compound, copper and / or a copper compound, molybdenum and / or a molybdenum compound, chromium and / or a Chromium compound, phosphorus and / or a phosphorus compound, manganese and / or a manganese compound or a mixture of two or more of these compounds are contained. 5. Combination preparation according to claim 4, characterized in that trace elements selected from a group comprising selenium and / or a selenium compound in amounts of 0.001 to 0.05 wt .-%, in particular 0.002 to 0.01 wt .-%, preferably 0.003 to 0.005 wt .-%, copper and / or a copper compound in amounts of 0.05 to 3 wt .-%, in particular 0.08 to 1 wt .-%, preferably 0.1 to 0.5 wt .-%, Molybdenum and / or a molybdenum compound in amounts of 0.0001 to 0.5 wt .-%, in particular 0.001 to 0.1 wt .-%, preferably 0.002 to 0.05 wt .-%, chromium and / or a chromium compound in Amounts from 0.0001 to 0.5 wt .-%, in particular 0.001 to 0.1 wt .-%, preferably 0.002 to 0.05 wt .-%, phosphorus and / or a phosphorus compound in amounts of 0.1 to 30 Wt .-%, in particular 1 to 20 wt .-%, preferably 10 to 15 wt .-%, manganese and / or a manganese compound in amounts of 0.05 to 3 wt .-%, in particular 0.08 to 1 wt. -%, preferably 0.1 to 0.5 wt .-%, based on the Gesamtge weight of the therapeutically active agents of the combination preparation are included. 6. Combination preparation according to one of claims 1 to 5, characterized in that precursors of A vitamins, especially, a- and ß-carotene, a- and ß-Cryptoxanthin and lycopene, and / or K vitamins, in particular K1, K2 , K3 based on the total weight of the therapeutically active agents of the combination preparation are included. 7. Combination preparation according to claim 6, characterized in that precursors of A vitamins, in particular, α- and β-carotene, α- and β-cryptoxanthin and lycopene, in amounts of 0.0001 to 0.05 wt .-%, in particular 0.0002 to 0.001% by weight, preferably 0.0003 to 0.0006% by weight, and / or K vitamins, in particular K1, K2, K3 in amounts of 0.05 to 3% by weight, in particular 0.08 to 1 wt .-%, preferably 0.1 to 0.5 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation are included. 8. Combination preparation according to one of claims 1 to 7, characterized in that omega-3 fatty acids, in particular DHA and / or EPA, are included. 11/12 Austrian Patent Office AT13 410U1 2013-12-15 9. Combination preparation according to claim 8, characterized in that omega-3 fatty acids, in particular DHA and / or EPA, in amounts of 2 to 70 wt .-%, in particular 10 to 50 wt .-%, preferably 20 to 40 wt. -%, based on the total weight of the therapeutically active agents of the combination preparation are included. 10. Combination preparation according to one of claims 1 to 9, characterized in that probiotics in amounts of 0.1 to 10 wt .-%, in particular 0.5 to 5 wt .-%, preferably 1 to 3 wt .-%, based are included on the total weight of the therapeutically active agents of the combination preparation. A combination preparation according to any one of claims 1 to 10 for use in the treatment of female infertility and for the improvement of oocyte quality and egg maturity for women over 35 years. For this no drawings 12/12